Communiqués de presse Archive - Page 18 of 19 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics will participate in HealthTech Investor Days

Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient

OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Use of Tedopi® to Treat Brain Metastasis

OSE Immunotherapeutics to Present at 5th Annual Immuno-Oncology: BD&L and Investment Forum

OSE Immunotherapeutics to Host Key Opinion Leader Meeting

OSE Immunotherapeutics Receives Notice of Allowance for New U.S. Patent Protecting OSE-127

OSE Immunotherapeutics Announces Publication on OSE-127

OSE Immunotherapeutics Announces Issuance of Two Patents For FR104

OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019

Précédent
1
…
15
16
17
18
19
Suivant